Table 1.
Position statements of selected major cardiovascular societies on the use of renin-angiotensin system inhibitors in the context of COVID-19 [41]
| Society | Position statement | Date, website |
|---|---|---|
| European Society of Hypertension | “The currently available data on COVID-19 infections do not support a differential use of RAS blockers (ACEI or ARBs) in COVID-19 patients” |
12 March 2020 https://www.eshonline.org/spotlights/esh-statement-on-covid-19/ |
| European Society of Cardiology | “… strongly recommend that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest that treatment with ACEi or ARBs should be discontinued because of the COVID-19 infection” |
13 March 2020 |
| Canadian Cardiovascular Society, Canadian Heart Failure Society | “The Canadian Cardiovascular Society and the Canadian Heart Failure Society strongly discourage the discontinuation of guideline-directed medical therapy (GDMT) involving Angiotensin-Converting Enzyme Inhibitors (ACEi), Angiotensin Receptor Blockers (ARB) or Angiotensin Receptor Neprilysin Inhibitors (ARNi) in hypertensive or heart failure patients as a result of the COVID-19 pandemic” |
15 March 2020 https://www.ccs.ca/images/Images_2020/CCS_CHFS_statement_regarding_COVID_EN.pdf |
| International Society of Hypertension | “… there is no good evidence to change the use of ACE-inhibitors or ARBs for the management of raised blood pressure in the context of avoiding or treating COVID-19 infection” |
16 March 2020 https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/ |
| American Heart Association, Heart Failure Society of America, American College of Cardiology | “… recommend continuation of RAAS antagonists for those patients who are currently prescribed such agents for indications for which these agents are known to be beneficial, such as heart failure, hypertension, or ischemic heart disease” |
17 March 2020 |